share_log

Assembly Biosciences | 10-Q: Quarterly report

Assembly Biosciences | 10-Q: Quarterly report

Assembly Biosciences | 10-Q:季度報表
美股sec公告 ·  05/09 04:21
牛牛AI助理已提取核心訊息
Assembly Biosciences, a biotechnology company, has reported collaboration revenue of $5.8 million for the first quarter ended March 31, 2024, under its Gilead Collaboration Agreement. This marks a significant milestone as there was no revenue in the same period the previous year. The company recognized this revenue over time using a cost-based input method, reflecting the transfer of services to Gilead. The total transaction price of the Gilead Collaboration Agreement was determined to be $90.7 million. Assembly Biosciences also reported a decrease in research and development expenses to $11.9 million, down from $14.5 million in the previous year, primarily due to the discontinuation of certain programs. General and administrative expenses also decreased to $4.6 million, a reduction from $5.0 million in the prior year. The company's...Show More
Assembly Biosciences, a biotechnology company, has reported collaboration revenue of $5.8 million for the first quarter ended March 31, 2024, under its Gilead Collaboration Agreement. This marks a significant milestone as there was no revenue in the same period the previous year. The company recognized this revenue over time using a cost-based input method, reflecting the transfer of services to Gilead. The total transaction price of the Gilead Collaboration Agreement was determined to be $90.7 million. Assembly Biosciences also reported a decrease in research and development expenses to $11.9 million, down from $14.5 million in the previous year, primarily due to the discontinuation of certain programs. General and administrative expenses also decreased to $4.6 million, a reduction from $5.0 million in the prior year. The company's net loss for the quarter was $9.1 million, and it ended the period with $80.5 million in deferred revenue. Assembly Biosciences expects to fund its operations into the second half of 2025 with its existing cash, cash equivalents, and marketable securities. The company's pipeline includes several programs targeting viral diseases, with clinical studies expected to initiate in 2024 for four of its programs. Assembly Biosciences has entered into significant collaboration agreements, including with Gilead Sciences, which has provided an upfront cash payment and equity investment, and retains opt-in rights to Assembly's pipeline programs. The company also concluded an agreement with Arbutus Biopharma and terminated a license agreement with Indiana University following the discontinuation of a development program.
生物技術公司Assembly Biosciences報告稱,根據其吉利德合作協議,截至2024年3月31日的第一季度合作收入爲580萬美元。這標誌着一個重要的里程碑,因爲去年同期沒有收入。隨着時間的推移,該公司使用基於成本的輸入法確認了這筆收入,反映了向吉利德轉移服務的情況。吉利德合作協議的總交易價格確定爲9,070萬美元。Assembly Biosciences還報告稱,研發費用從去年的1,450萬美元減少至1190萬美元,這主要是由於某些計劃的終止。一般和管理費用也從上一年的500萬美元減少到460萬美元。該公司本季度的淨虧損爲910萬美元,期末的遞延收入爲8,050萬美元。Assembl...展開全部
生物技術公司Assembly Biosciences報告稱,根據其吉利德合作協議,截至2024年3月31日的第一季度合作收入爲580萬美元。這標誌着一個重要的里程碑,因爲去年同期沒有收入。隨着時間的推移,該公司使用基於成本的輸入法確認了這筆收入,反映了向吉利德轉移服務的情況。吉利德合作協議的總交易價格確定爲9,070萬美元。Assembly Biosciences還報告稱,研發費用從去年的1,450萬美元減少至1190萬美元,這主要是由於某些計劃的終止。一般和管理費用也從上一年的500萬美元減少到460萬美元。該公司本季度的淨虧損爲910萬美元,期末的遞延收入爲8,050萬美元。Assembly Biosciences預計將在2025年下半年使用其現有現金、現金等價物和有價證券爲其運營提供資金。該公司的計劃包括多個針對病毒性疾病的項目,其中四個項目的臨床研究預計將於2024年啓動。Assembly Biosciences已經簽訂了重要的合作協議,包括與吉利德科學簽訂了重要的合作協議,後者提供了預付的現金支付和股權投資,並保留了Assembly管道計劃的選擇權。該公司還與Arbutus Biopharma簽訂了協議,並在開發計劃中止後終止了與印第安納大學的許可協議。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。